Faron Pharmaceuticals Oy PDMR Shareholding (3448O)

TIDMFARN

RNS Number : 3448O

Faron Pharmaceuticals Oy

16 May 2018

Faron Pharmaceuticals Oy

("Faron" or the "Company")

PDMR Dealing

TURKU - FINLAND, 16 May 2018 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, announces that on 16 May 2018 it was notified that on 15 May 2018 Dr Jonathan Knowles, a Non-Executive Director of Faron has acquired 7,200 ordinary shares in Faron at an average price of 118.00 pence per ordinary share and 1,300 ordinary shares in Faron at an average price of 116.97 pence per ordinary share.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 
 Notification of a Transaction pursuant to Article 
  19(1) of Regulation (EU) No. 596/2014 
------------------------------------------------------------------------- 
 1     Details of the person discharging managerial 
        responsibilities/person closely associated 
----  ------------------------------------------------------------------- 
 a.    Name                       Jonathan Knowles 
                                 ---------------------------------------- 
 2     Reason for 
        notification 
----  -------------------------  ---------------------------------------- 
 a.    Position/Status            Person discharging managerial 
                                   responsibilities 
 
                                   Non-Executive Director 
----  -------------------------  ---------------------------------------- 
 b.    Initial notification/      Initial Notification 
        Amendment 
----  -------------------------  ---------------------------------------- 
 3     Details of the issuer, emission allowance 
        market participant, auction platform, auctioneer 
        or auction monitor 
      ------------------------------------------------------------------- 
 a.    Name                       Faron Pharmaceuticals Oy 
----  -------------------------  ---------------------------------------- 
 b.    LEI                        7437009H31TO1DC0EB42 
----  -------------------------  ---------------------------------------- 
 4     Details of the transaction(s): section to 
        be repeated for (i) each type of instrument; 
        (ii) each type of transaction; (iii) each 
        date; and (iv) each place where transactions 
        have been conducted 
----  ------------------------------------------------------------------- 
 a.    Description                Ordinary shares 
        of the financial 
        instrument,                ISIN: FI4000153309 
        type of instrument 
 
        Identification 
        Code 
----  -------------------------  ---------------------------------------- 
 b.    Nature of the              Purchase of ordinary shares 
        transaction 
----  -------------------------  ---------------------------------------- 
 
 c.    Price(s) and                      Price(s)          Volume(s) 
        volume(s) 
----  -------------------------         ----------------  ----------- 
                                         118.00 GBPp       7,200 
     116.97 GBPp                                            1,300 
   -----------------------------------------------------  ----------- 
 
 d.    Aggregated 
        information 
                                    8,500 
        - Aggregated 
        Volume                      GBP 10,016.61 
 
        - Price 
----  -------------------------  ---------------------------------------- 
 e.    Date of the                May 15, 2018 
        transaction 
----  -------------------------  ---------------------------------------- 
 f.    Place of the               Turku 
        transaction 
----  -------------------------  ---------------------------------------- 
 
 

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer

[e-mail]

Consilium Strategic Communications

Mary-Jane Elliott, Philippa Gardner, Matthew Neal, Lindsey Neville

Phone: [phone]

E-mail: [e-mail]

Westwicke Partners, IR (US)

Chris Brinzey

Phone: [phone]

E-Mail: [e-mail]

Panmure Gordon (UK) Limited, Nomad and Broker

Freddy Crossley, Emma Earl, Ryan McCarthy

Phone: [phone]

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company's lead candidate Traumakine, to prevent vascular leakage and organ failures, has completed a Phase III clinical trial in Acute Respiratory Distress Syndrome ("ARDS"). An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm ("RAAA"). Faron's second candidate Clevegen is a ground breaking preclinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology ("TIET") may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHSFEFMMFASEII

(END) Dow Jones Newswires

May 16, 2018 12:53 ET (16:53 GMT)